KRAS and cancer: Regardless of their size and prevalence, these components frequently share identical oncogenic alterations in cancer-drivers such as mutations in EGFR, KRAS, AKT1, ERBB2, and PI3KCA genes or fusions of ALK and RET genes, with frequencies resembling those in pure LAC, thereby suggesting a potential phenotypic transition [7,238].